There were no differences between cohorts in 30-day readmission or mortality.
August 30, 2017
A newly-published report on the outcomes of more than 1,300 mesothelioma patients shows that survival may not depend on whether a patient has lung-sparing or lung-removing surgery. Surviving Mesothelioma has the details. Click here to read the full article.
The study utilized data from the National Cancer Database and included malignant mesothelioma patients who had either lung-removing extrapleural pneumonectomy surgery or lung-sparing pleurectomy/decortication.
“Median overall survival in the EPP and P/D groups was 19 versus 16 months; no differences were observed after propensity-matching,” reports author and radiation oncologist Vivek Verma, MD, of the University of Nebraska Medical Center in Omaha. “There were no differences between cohorts in 30-day readmission or mortality.”
The report in the Journal of Thoracic Oncology also revealed that P/D was nearly four times as common as EPP and that people who underwent EPP tended to be younger, live in more rural areas, and be treated at academic centers.
“This study suggests that mesothelioma surgery decisions may have a lot to do with where a person lives and what kind of a surgeon he or she has access to, rather than just the patient’s clinical considerations,” says Alex Strauss, Managing Editor for Surviving Mesothelioma.
To read more about the new surgery study findings, see New Research Finds Little Survival Difference Between Mesothelioma Surgeries, now available on the Surviving Mesothelioma website.
Verma, V, et al, “National Cancer Data Base Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma”, August 23, 2017,…